1.Dixon, J. M. Endocrine Resistance in Breast Cancer. New J. Sci. 2014, 1–27 (2014).
2.Santer, F. R., Erb, H. H. H. & McNeill, R. V. Therapy escape mechanisms in the malignant prostate. Semin. Cancer Biol. 35, 133–44 (2015).
3.Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., Yang, Y. C., Nyquist, M. D., Mostaghel, E., Hsieh, A. C., Zhang, X., Corey, E., Brown, L. G., Nguyen, H. M., Pienta, K., et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 32, 474–489.e6 (2017).
4.Murray, J. I., West, N. R., Murphy, L. C. & Watson, P. H. Intratumoural inflammation and endocrine resistance in breast cancer. Endocr. Relat. Cancer 22, R51–67 (2015).
5.Arnedos, M., Bihan, C., Delaloge, S. & Andre, F. Triple-negative breast cancer: are we making headway at least? Ther. Adv. Med. Oncol. 4, 195–210 (2012).
6.Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I. & Eisenberger, M. A. Small cell carcinoma of the prostate. Nature Reviews Urology (2014).
7.Lewis, A.M., Varghese, S., Xu, H. & Alexander, H. R. Interleukin–1 and cancer progression: the emerging role of interleukin–1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med. 4, 48 (2006).
8.Al-Hassan, A. A. Prognostic Value of Proinflammatory Cytokines in Breast Cancer. J. Biomol. Res. Ther. 01, (2013).
9.Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I. & Morales-Montor, J. The Role of Cytokines in Breast Cancer Development and Progression. J. Interf. Cytokine Res. 35, 1–16 (2015).
10.Liu, Q., Russell, M. R., Shahriari, K., Jernigan, D. L., Lioni, M. I., Garcia, F. U. & Fatatis, A. Interleukin–1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Res. 73, 3297–305 (2013).
11.Pantschenko, A. G., Pushkar, I., Anderson, K. H., Wang, Y., Miller, L. J., Kurtzman, S. H., Barrows, G. & Kreutzer, D. L. The interleukin–1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int. J. Oncol. 23, 269–84 (2003).
12.Soria, G., Ofri-Shahak, M., Haas, I., Yaal-Hahoshen, N., Leider-Trejo, L., Leibovich-Rivkin, T., Weitzenfeld, P., Meshel, T., Shabtai, E., Gutman, M. & Ben-Baruch, A. Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL–1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11, 130 (2011).
13.Tazaki, E., Shimizu, N., Tanaka, R., Yoshizumi, M., Kamma, H., Imoto, S., Goya, T., Kozawa, K., Nishina, A. & Kimura, H. Serum cytokine profiles in patients with prostate carcinoma. Exp. Ther. Med. 2, 887–891 (2011).
14.Chavey, C., Bibeau, F., Gourgou-Bourgade, S., Burlinchon, S., Boissière, F., Laune, D., Roques, S. & Lazennec, G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9, R15 (2007).
15.Miller, L. J., Kurtzman, S. H., Anderson, K., Wang, Y., Stankus, M., Renna, M., Lindquist, R., Barrows, G. & Kreutzer, D. L. Interleukin–1 family expression in human breast cancer: interleukin–1 receptor antagonist. Cancer Invest. 18, 293–302 (2000).
16.Singer, C. F., Hudelist, G., Gschwantler-Kaulich, D., Fink-Retter, a, Mueller, R., Walter, I., Czerwenka, K. & Kubista, E. Interleukin–1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity. Int. J. Gynecol. Cancer 16 Suppl 2, 556–9 (2006).
17.Zhang, B., Kwon, O. J., Henry, G., Malewska, A., Wei, X., Zhang, L., Brinkley, W., Zhang, Y., Castro, P. D., Titus, M., Chen, R., Sayeeduddin, M., Raj, G. V., Mauck, R., Roehrborn, C., Creighton, C. J., Strand, D. W., Ittmann, M. M. & Xin, L. Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Mol. Cell 63, 976–989 (2016).
18.Thomas-Jardin, S. E., Kanchwala, M. S., Jacob, J., Merchant, S., Meade, R. K., Gahnim, N. M., Nawas, A. F., Xing, C. & Delk, N. A. Identification of an IL–1-induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR- PCa cells. Prostate 78, 595–606 (2018).
19.Nawas, A. F., Mistry, R., Narayanan, S., Thomas-Jardin, S. E., Ramachandran, J., Ravichandran, J., Neduvelil, E., Luangpanh, K. & Delk, N. A. IL–1 induces p62/SQSTM1 and autophagy in ERα+ /PR+ BCa cell lines concomitant with ERα and PR repression, conferring an ERα- /PR- BCa-like phenotype. J. Cell. Biochem. 120, 1477–1491 (2018).
20.Puissant, A., Fenouille, N. & Auberger, P. When autophagy meets cancer through p62/SQSTM1. Am. J. Cancer Res. 2, 397–413 (2012).
21.Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H. & Johansen, T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603–614 (2005).
22.Cemma, M., Kim, P. K. & Brumell, J. H. The ubiquitin-binding adaptor proteins p62/SQSTM1 and NDP52 are recruited independently to bacteria-associated microdomains to target Salmonella to the autophagy pathway. Autophagy 7, 341–345 (2011).
23.Ding, W. X., Ni, H. M., Li, M., Liao, Y., Chen, X., Stolz, D. B., Dorn, G. W. & Yin, X. M. Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J. Biol. Chem. 285, 27879–27890 (2010).
24.Kim, P. K., Hailey, D. W., Mullen, R. T. & Lippincott-Schwartz, J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. Proc. Natl. Acad. Sci. U.S. A. 105, 20567–20574 (2008).
25.Itakura, E. & Mizushima, N. p62 targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. J. Cell Biol. 192, 17–27 (2011).
26.Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J. A., Outzen, H., Øvervatn, A., Bjørkøy, G. & Johansen, T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy*[S]. J. Biol. Chem. 282, 24131–24145 (2007).
27.Wooten, M. W., Geetha, T., Seibenhener, M. L., Babu, J. R., Diaz-Meco, M. T. & Moscat, J. The p62 scaffold regulates nerve growth factor-induced NF-kB activation by influencing TRAF6 polyubiquitination. J. Biol. Chem. 280, 35625–35629 (2005).
28.Nakamura, K., Kimple, A. J., Siderovski, D. P. & Johnson, G. L. PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-κB activation. J. Biol. Chem. 285, 2077–2089 (2010).
29.Dodson, M., Redmann, M., Rajasekaran, N. S., Darley-Usmar, V. & Zhang, J. KEAP1-NRF2 signalling and autophagy in protection against oxidative and reductive proteotoxicity. Biochem. J. 469, 347–355 (2015).
30.Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., Kim, M., Nishito, Y., Iemura, S., Natsume, T., Ueno, T., Kominami, E., Motohashi, H., Tanaka, K. & Yamamoto, M. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 12, 213–223 (2010).
31.Copple, I. M., Lister, A., Obeng, A.D., Kitteringham, N. R., Jenkins, R. E., Layfield, R., Foster, B. J., Goldring, C. E. & Park, B. K. Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J. Biol. Chem. 285, 16782–16788 (2010).
32.Jo, A., Denduluri, S., Zhang, B., Wang, Z., Yin, L., Yan, Z., Kang, R., Shi, L. L., Mok, J., Lee, M. J. & Haydon, R. C. The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis. 1, 149–161 (2014).
33.Cheung, M. & Briscoe, J. Neural crest development is regulated by the transcription factor Sox9. Development (2003).
34.Akiyama, H., Chaboissier, M. C., Behringer, R. R., Rowitch, D. H., Schedl, A., Epstein, J. A. & De Crombrugghe, B. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc. Natl. Acad. Sci. U.S. A. (2004). doi:10.1073/pnas.0401711101
35.Wilhelm, D., Hiramatsu, R., Mizusaki, H., Widjaja, L., Combes, A. N., Kanai, Y. & Koopman, P. SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development. J. Biol. Chem. (2007). doi:10.1074/jbc.M609578200
36.S., A. FastQC: a quality control tool for high throughput sequence data. (2010).
37.S., W. FastQ Screen: quality control tool to screen a library of sequences in FastQ format against a set of sequence databasesNo Title. (2011).
38.Aronesty, E. Comparison of Sequencing Utility Programs. Open Bioinforma. J. 7, 1–8 (2013).
39.Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R. & Salzberg, S. L. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
40.Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
41.Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2009).
42.Chang, M. A., Patel, V., Gwede, M., Morgado, M., Tomasevich, K., Fong, E. L. L., Farach-Carson, M. C. C. & Delk, N. A. IL–1β Induces p62/SQSTM1 and Represses Androgen Receptor Expression in Prostate Cancer Cells. J. Cell. Biochem. 115, 2188–2197 (2014).
43.Wang, L., Kim, D., Wise, J. T. F., Shi, X., Zhang, Z. & DiPaola, R. S. p62 as a therapeutic target for inhibition of autophagy in prostate cancer. Prostate 78, 390–400 (2018).
44.Xu, L.-Z., Li, S., Zhou, W., Kang, Z., Zhang, Q., Kamran, M., Xu, J., Liang, D., Wang, C.-L., Hou, Z., Wan, X., Wang, H.-J., Lam, E. W.-F., Zhao, Z.-W. & Liu, Q. p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. Oncogene 36, 304–317 (2017).
45.Chang, M. A., Morgado, M., Warren, C. R., Hinton, C. V., Farach-Carson, M. C. & Delk, N. A. p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines. Prostate 74, 149–63 (2014).
46.Puvirajesinghe, T. M., Bertucci, F., Jain, A., Scerbo, P., Belotti, E., Audebert, S., Sebbagh, M., Lopez, M., Brech, A., Finetti, P., Charafe-Jauffret, E., Chaffanet, M., Castellano, R., Restouin, A., Marchetto, S., Collette, Y., Gonçalvès, A., Macara, I., Birnbaum, D., et al. Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2–JNK signalling in breast cancer. Nat. Commun. 7, 10318 (2016).
47.Li, S.-S., Xu, L.-Z., Zhou, W., Yao, S., Wang, C.-L., Xia, J.-L., Wang, H.-F., Kamran, M., Xue, X.-Y., Dong, L., Wang, J., Ding, X.-D., Bella, L., Bugeon, L., Xu, J., Zheng, F.-M., Dallman, M. J., Lam, E. W. F. & Liu, Q. p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis. Carcinogenesis 38, 1092–1103 (2017).
48.Moscat, J. & Diaz-Meco, M. T. P62 At the Crossroads of Autophagy, Apoptosis, and Cancer. Cell 137, 1001–4 (2009).
49.Alves, C. L., Elias, D., Lyng, M., Bak, M., Kirkegaard, T., Lykkesfeldt, A. E. & Ditzel, H. J. High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer. Clin. Cancer Res. (2016). doi:10.1158/1078–0432.CCR–15–1984
50.Donohue, E., Balgi, A.D., Komatsu, M. & Roberge, M. Induction of covalently crosslinked p62 oligomers with reduced binding to polyubiquitinated proteins by the autophagy inhibitor verteporfin. PLoS One (2014). doi:10.1371/journal.pone.0114964
51.Cai, T., Santi, R., Tamanini, I., Galli, I. C., Perletti, G., Bjerklund Johansen, T. E. & Nesi, G. Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. Int. J. Mol. Sci. 20, 3833 (2019).
52.Valenta, T., Hausmann, G. & Basler, K. The many faces and functions of β-catenin. EMBO J. 31, 2714–36 (2012).
53.Pohl, S.-G., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P. & Dharmarajan, A. Wnt signaling in triple-negative breast cancer. Oncogenesis 6, e310 (2017).
54.Murillo-Garzón, V. & Kypta, R. WNT signalling in prostate cancer. Nat. Rev. Urol. 14, 683–696 (2017).
55.Bikfalvi, A., Klein, S., Pintucci, G. & Rifkin, D. B. Biological roles of fibroblast growth factor–2. Endocr. Rev. 18, 26–45 (1997).
56.Teng, Y., Guo, B., Mu, X. & Liu, S. KIF26B promotes cell proliferation and migration through the FGF2/ERK signaling pathway in breast cancer. Biomed. Pharmacother. 108, 766–773 (2018).
57.Polnaszek, N., Kwabi-Addo, B., Peterson, L. E., Ozen, M., Greenberg, N. M., Ortega, S., Basilico, C. & Ittmann, M. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 63, 5754–60 (2003).
58.Martínez-Reza, I., Díaz, L. & García-Becerra, R. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer. J. Biomed. Sci. 24, 90 (2017).
59.Tse, B. W. C., Scott, K. F. & Russell, P. J. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer 2012, 128965 (2012).
60.Kitamura, H., Torigoe, T., Asanuma, H., Hisasue, S.-I., Suzuki, K., Tsukamoto, T., Satoh, M. & Sato, N. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology 48, 157–61 (2006).
61.Burdelski, C., Reiswich, V., Hube-Magg, C., Kluth, M., Minner, S., Koop, C., Graefen, M., Heinzer, H., Tsourlakis, M. C., Wittmer, C., Huland, H., Simon, R., Schlomm, T., Sauter, G. & Steurer, S. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. Clin. Cancer Res. 21, 3471–3479 (2015).
62.Domenici, G., Aurrekoetxea-Rodríguez, I., Simões, B. M., Rábano, M., Lee, S. Y., Millán, J. S., Comaills, V., Oliemuller, E., López-Ruiz, J. A., Zabalza, I., Howard, B. A., Kypta, R. M. & Vivanco, M. d. M. A Sox2–Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene 38, 3151–3169 (2019).
63.Thomsen, M. K., Ambroisine, L., Wynn, S., Cheah, K. S. E., Foster, C. S., Fisher, G., Berney, D. M., Møller, H., Reuter, V. E., Scardino, P., Cuzick, J., Ragavan, N., Singh, P. B., Martin, F. L., Butler, C. M., Cooper, C. S., Swain, A. & Transatlantic Prostate Group. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 70, 979–87 (2010).
64.Ryoo, I.-G., Choi, B.-H., Ku, S.-K. & Kwak, M.-K. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance. Redox Biol. 17, 246–258 (2018).
65.Ma, F., Ye, H., He, H. H., Gerrin, S. J., Chen, S., Tanenbaum, B. A., Cai, C., Sowalsky, A. G., He, L., Wang, H., Balk, S. P. & Yuan, X. SOX9 drives WNT pathway activation in prostate cancer. J. Clin. Invest. 126, 1745–58 (2016).